Dermatomycoses - Pipeline Review, H2 2016

  • ID: 3984499
  • Drug Pipelines
  • 61 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Biolab Farmaceutica Ltda
  • Dermala Inc
  • Helix BioMedix Inc
  • Novan Inc
  • Sol-Gel Technologies Ltd
  • TGV-Laboratories
  • MORE
Dermatomycoses - Pipeline Review, H2 2016

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Dermatomycoses - Pipeline Review, H2 2016, provides an overview of the Dermatomycoses (Infectious Disease) pipeline landscape.

Dermatophytes cause fungal infections of keratinized tissues, e.g. skin, hair and nails. The organisms belong to 3 genera, Trichophyton, Epidermophyton and Microsporum. Dermatophytes may be grouped into 3 categories based on host preference and natural habitat. Anthropophilic species predominantly infect humans, geophilic species are soil based and may infect both humans and animals, zoophilic species generally infect non-human mammals.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Dermatomycoses - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Dermatomycoses (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dermatomycoses (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Dermatomycoses and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 4, 1, 5 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively. Dermatomycoses.

Dermatomycoses (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Dermatomycoses (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Dermatomycoses (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Dermatomycoses (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Dermatomycoses (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Dermatomycoses (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Dermatomycoses (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Dermatomycoses (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Biolab Farmaceutica Ltda
  • Dermala Inc
  • Helix BioMedix Inc
  • Novan Inc
  • Sol-Gel Technologies Ltd
  • TGV-Laboratories
  • MORE
List of Tables

List of Figures

Introduction

Dermatomycoses Overview

Therapeutics Development

Pipeline Products for Dermatomycoses - Overview

Pipeline Products for Dermatomycoses - Comparative Analysis

Dermatomycoses - Therapeutics under Development by Companies

Dermatomycoses - Therapeutics under Investigation by Universities/Institutes

Dermatomycoses - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Unknown Stage Products

Dermatomycoses - Products under Development by Companies

Dermatomycoses - Products under Investigation by Universities/Institutes

Dermatomycoses - Companies Involved in Therapeutics Development

Anacor Pharmaceuticals Inc

Biolab Farmaceutica Ltda

Blueberry Therapeutics Ltd

Daewoong Pharmaceutical Co Ltd

Dermala Inc

Helix BioMedix Inc

Novan Inc

Sol-Gel Technologies Ltd

TGV-Laboratories

Viamet Pharmaceuticals Inc

Vyome Biosciences Pvt Ltd

Dermatomycoses - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

AN-2718 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BB-2603 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

clotrimazole - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dapaconazole - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug for Athlete's Foot - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DWP-06081 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

E-06 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HB-1275 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

luliconazole - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Myc-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nitric oxide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SB-208 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Fungal Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VT-1161 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Dermatomycoses - Dormant Projects

Dermatomycoses - Product Development Milestones

Featured News & Press Releases

Jul 21, 2016: Novan Announces First Patient Dosed in Phase 2 Anti-Fungal Program

Jul 15, 2015: Viamet to Present at American Podiatric Medical Association 2015 Annual Scientific Meeting

Jul 09, 2014: Viamet Reports Additional Positive Interim Results of Phase 2 Studies of VT-1161 with Moderate to Severe Interdigital Tinea Pedis

Mar 12, 2014: Viamet Reports Positive Interim Results of Phase 2 Interdigital Tinea Pedis Study of VT-1161

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Dermatomycoses, H2 2016

Number of Products under Development for Dermatomycoses - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Comparative Analysis by Unknown Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Dermatomycoses - Pipeline by Anacor Pharmaceuticals Inc, H2 2016

Dermatomycoses - Pipeline by Biolab Farmaceutica Ltda, H2 2016

Dermatomycoses - Pipeline by Blueberry Therapeutics Ltd, H2 2016

Dermatomycoses - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2016

Dermatomycoses - Pipeline by Dermala Inc, H2 2016

Dermatomycoses - Pipeline by Helix BioMedix Inc, H2 2016

Dermatomycoses - Pipeline by Novan Inc, H2 2016

Dermatomycoses - Pipeline by Sol-Gel Technologies Ltd, H2 2016

Dermatomycoses - Pipeline by TGV-Laboratories, H2 2016

Dermatomycoses - Pipeline by Viamet Pharmaceuticals Inc, H2 2016

Dermatomycoses - Pipeline by Vyome Biosciences Pvt Ltd, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Dermatomycoses - Dormant Projects, H2 2016

List of Figures

Number of Products under Development for Dermatomycoses, H2 2016

Number of Products under Development for Dermatomycoses - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Targets, H2 2016

Number of Products by Stage and Targets, H2 2016

Number of Products by Mechanism of Actions, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Anacor Pharmaceuticals Inc
  • Biolab Farmaceutica Ltda
  • Blueberry Therapeutics Ltd
  • Daewoong Pharmaceutical Co Ltd
  • Dermala Inc
  • Helix BioMedix Inc
  • Novan Inc
  • Sol-Gel Technologies Ltd
  • TGV-Laboratories
  • Viamet Pharmaceuticals Inc
  • Vyome Biosciences Pvt Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll